Impact of early interferon-β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort

• DOI: 10.1016/j.biopha.2021.112572
• Publication Date: 2021-12-22T03:35:23Z
• Authors: Sonsoles Salto-Al...; Zaira R. Palacios...; José Ramón Arribas; Juan Berenguer; Jordi Carratalà; Inmaculada Jarrín; Pablo Ryan; Marta de Miguel-M...; Jesús Rodríguez-Baño; Jerónimo Pachón
• Keywords: Clinical endpoint; Post-hoc analysis

Interferon-β is an attractive drug for repurposing and use in the treatment of COVID-19, based on its vitro antiviral activity encouraging results from clinical trials. The aim this study was to analyze impact early interferon-β patients admitted with COVID-19 during first wave pandemic.This post hoc analysis a COVID-19@Spain multicenter cohort included 3808 consecutive adult hospitalized 1 January 17 March 2020. primary endpoint 30-day all-cause mortality, main exposure interest subcutaneous administration interferon-β, defined as if started ≤ 3 days admission. Multivariate logistic Cox regression analyses were conducted identify associations different variables receiving therapy assess mortality. A propensity score calculated used both control confounders perform matched analysis.Overall, 683 (17.9%) received therapy. These more severely ill. Adjusted HR mortality 1.03 (95% CI, 0.82-1.30) overall cohort, 0.96 (0.82-1.13) PS-matched subcohort, 0.89 (0.60-1.32) when analyzed time-dependent variable.In patients, after hospital admission did not show association lower Whether might be useful earlier stages disease or specific subgroups requires further research.